Business Context and Reporting Period
This Form 8-K filing by Lantronix, Inc. is dated May 15, 2012. The report addresses a corporate governance issue regarding the composition of the Board of Directors and the company's compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance matter and contains no financial performance data.
Material Changes
On May 14, 2012, Thomas M. Wittenschlaeger voluntarily resigned as a director, chairman of the board, and member of all board committees. Consequently, the Company's Audit Committee no longer met the requirement of having at least three independent directors under Nasdaq Listing Rule 5605(c)(2)(A). On May 15, 2012, the Company received formal notification from Nasdaq regarding this non-compliance.
Outlook, Risks, and Management Commentary
Nasdaq has granted the Company a cure period to regain compliance with the listing rule. The deadline is the earlier of the Company's next annual shareholders' meeting or May 14, 2013. However, if the next annual shareholders' meeting is held on or before November 12, 2012, the Company must evidence compliance by November 12, 2012. Management intends to identify candidates and appoint a director who satisfies the independence requirements prior to the expiration of the cure period.
Investor Verification Checklist
- Verify the appointment of a new independent director to the Audit Committee before the applicable cure deadline.
- Confirm the date of the next annual shareholders' meeting to determine the specific compliance deadline.
- Monitor future filings for any updates on the Board composition or potential delisting risks if the cure period expires without resolution.